vs
Side-by-side financial comparison of Ellington Financial Inc. (EFC) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $78.2M, roughly 1.1× Ellington Financial Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 8.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 1.8%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
EFC vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $86.8M |
| Net Profit | $22.6M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 7.4% | -84.7% |
| Net Margin | 28.9% | — |
| Revenue YoY | 8.7% | 17.7% |
| Net Profit YoY | -26.2% | — |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $78.2M | $86.8M | ||
| Q3 25 | $82.8M | $67.5M | ||
| Q2 25 | $92.5M | $60.0M | ||
| Q1 25 | $82.9M | $49.3M | ||
| Q4 24 | $72.0M | $73.7M | ||
| Q3 24 | $67.0M | $58.6M | ||
| Q2 24 | $91.2M | $31.1M | ||
| Q1 24 | $75.5M | $715.0K |
| Q4 25 | $22.6M | — | ||
| Q3 25 | $29.5M | $-91.3M | ||
| Q2 25 | $42.9M | $-111.7M | ||
| Q1 25 | $31.6M | $-116.2M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $16.2M | $-83.5M | ||
| Q2 24 | $52.3M | $-97.1M | ||
| Q1 24 | $26.9M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 7.4% | -84.7% | ||
| Q3 25 | 31.1% | -140.7% | ||
| Q2 25 | 38.3% | -189.8% | ||
| Q1 25 | 37.3% | -245.8% | ||
| Q4 24 | 28.0% | -117.5% | ||
| Q3 24 | 24.0% | -152.1% | ||
| Q2 24 | 52.8% | -327.6% | ||
| Q1 24 | 42.2% | -16464.6% |
| Q4 25 | 28.9% | — | ||
| Q3 25 | 35.7% | -135.3% | ||
| Q2 25 | 46.4% | -186.2% | ||
| Q1 25 | 38.2% | -235.5% | ||
| Q4 24 | 42.6% | — | ||
| Q3 24 | 24.1% | -142.7% | ||
| Q2 24 | 57.4% | -312.2% | ||
| Q1 24 | 35.6% | -15800.8% |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.29 | — | ||
| Q2 25 | $0.45 | $-0.33 | ||
| Q1 25 | $0.35 | $-0.36 | ||
| Q4 24 | $0.23 | $-0.24 | ||
| Q3 24 | $0.19 | $-0.28 | ||
| Q2 24 | $0.62 | $-0.34 | ||
| Q1 24 | $0.32 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $698.6M |
| Total Assets | $19.4B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $201.9M | $297.0M | ||
| Q3 25 | $184.8M | $300.8M | ||
| Q2 25 | $211.0M | $301.2M | ||
| Q1 25 | $203.3M | $359.7M | ||
| Q4 24 | $192.4M | $323.8M | ||
| Q3 24 | $217.7M | $397.5M | ||
| Q2 24 | $198.5M | $412.5M | ||
| Q1 24 | $187.5M | $356.2M |
| Q4 25 | $1.8B | $698.6M | ||
| Q3 25 | $1.8B | $702.3M | ||
| Q2 25 | $1.7B | $698.5M | ||
| Q1 25 | $1.6B | $767.9M | ||
| Q4 24 | $1.6B | $710.4M | ||
| Q3 24 | $1.6B | $773.5M | ||
| Q2 24 | $1.6B | $768.5M | ||
| Q1 24 | $1.5B | $680.0M |
| Q4 25 | $19.4B | $913.2M | ||
| Q3 25 | $17.8B | $904.9M | ||
| Q2 25 | $17.1B | $907.4M | ||
| Q1 25 | $16.6B | $966.7M | ||
| Q4 24 | $16.3B | $910.4M | ||
| Q3 24 | $16.0B | $991.1M | ||
| Q2 24 | $15.1B | $964.3M | ||
| Q1 24 | $15.1B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-925.5M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | 0.0% | 10.7% |
| Cash ConversionOCF / Net Profit | -40.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-925.5M | $-52.6M | ||
| Q3 25 | $-290.4M | $-78.7M | ||
| Q2 25 | $-210.5M | $-67.4M | ||
| Q1 25 | $-126.4M | $-103.7M | ||
| Q4 24 | $-430.5M | $-73.3M | ||
| Q3 24 | $-141.7M | $-59.0M | ||
| Q2 24 | $-88.6M | $-98.4M | ||
| Q1 24 | $-59.5M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | 0.0% | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 0.0% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 583.4% |
| Q4 25 | -40.92× | — | ||
| Q3 25 | -9.84× | — | ||
| Q2 25 | -4.90× | — | ||
| Q1 25 | -3.99× | — | ||
| Q4 24 | -14.04× | — | ||
| Q3 24 | -8.76× | — | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EFC
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
